Spontaneously hypertensive rats display reduced microglial activation in response to ischemic stroke and lipopolysaccharide by De Geyter, Deborah et al.
  
 University of Groningen
Spontaneously hypertensive rats display reduced microglial activation in response to ischemic
stroke and lipopolysaccharide






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2012
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
De Geyter, D., Stoop, W., Zgavc, T., Sarre, S., Michotte, Y., De Keyser, J., & Kooijman, R. (2012).
Spontaneously hypertensive rats display reduced microglial activation in response to ischemic stroke and
lipopolysaccharide. Journal of neuroinflammation, 9, [114]. https://doi.org/10.1186/1742-2094-9-114
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
RESEARCH Open Access
Spontaneously hypertensive rats display reduced
microglial activation in response to ischemic
stroke and lipopolysaccharide
Deborah De Geyter1, Wendy Stoop1, Tine Zgavc2, Sophie Sarre2, Yvette Michotte2, Jacques De Keyser3,4 and
Ron Kooijman1*
Abstract
Background: For successful translation to clinical stroke studies, the Stroke Therapy Academic Industry Round Table
criteria have been proposed. Two important criteria are testing of therapeutic interventions in conscious animals
and the presence of a co-morbidity factor. We chose to work with hypertensive rats since hypertension is an
important modifiable risk factor for stroke and influences the clinical outcome. We aimed to compare the
susceptibility to ischemia in hypertensive rats with those in normotensive controls in a rat model for induction of
ischemic stroke in conscious animals.
Methods: The vasoconstrictor endothelin-1 was stereotactically applied in the vicinity of the middle cerebral artery
of control Wistar Kyoto rats (WKYRs) and Spontaneously Hypertensive rats (SHRs) to induce a transient decrease in
striatal blood flow, which was measured by the Laser Doppler technique. Infarct size was assessed histologically by
Cresyl Violet staining. Sensory-motor functions were measured at several time points using the Neurological Deficit
Score. Activation of microglia and astrocytes in the striatum and cortex was investigated by immunohistochemistry
using antibodies against CD68/Iba-1 and glial fibrillary acidic protein.
Results and conclusions: The SHRs showed significantly larger infarct volumes and more pronounced sensory-motor
deficits, compared to the WKYRs at 24 h after the insult. However, both differences disappeared between 24 and 72 h. In
SHRs, microglia were less susceptible to activation by lipopolysaccharide and there was a reduced microglial activation
after induction of ischemic stroke. These quantitative and qualitative differences may be relevant for studying the efficacy
of new treatments for stroke in accordance to the Stroke Therapy Academic Industry Round Table criteria.
Keywords: Focal cerebral ischemia, Endothelin-1, Hypertension, Glial cells, Blood flow
Background
Many clinical trials with neuroprotective drugs in patients
with acute ischemic stroke have yielded disappointing
results [1,2]. This failure may be due to the use of in-
adequate animal models. To facilitate translation to the
clinic, the Stroke Therapy Academic Industry Round table
(STAIR) has developed criteria for more clinically relevant
research in animal models of ischemic stroke. The current
paper evaluates a model for translational research fulfilling
the STAIR criteria. An important requirement is testing of
drugs in animal models with a co-morbidity, such as dia-
betes or hypertension. We have chosen hypertension, be-
cause it is a modifiable risk factor for both ischemic and
hemorrhagic stroke [3]. In addition, more than 50% of
stroke patients show an acute hypertensive response, which
appears to be related to a poor clinical outcome [4,5], and
pre-existing hypertension can exacerbate this response to
acute stroke [6]. Two different rat strains with spontaneous
hypertension have often been used as an animal model for
ischemic stroke. Spontaneously hypertensive rats (SHRs)
were developed in the Kyoto School of Medicine in Japan
from an outbred Wistar Kyoto male rat (WKYR) with
marked elevation of blood pressure mated to a female with
slightly elevated blood pressure. The other model [7] is the
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stroke-prone spontaneously hypertensive rat (SPSHR),
which develops spontaneous strokes. This model exhibits
increased sensitivity to experimental stroke which may, in
addition to genetically determined hypertension, also be
due to additional genetic factors [8]. Although additional
genetic factors exacerbating the effects of experimental
stroke cannot be excluded in SHRs, we preferred to use this
strain to study the effects of hypertension on experimental
ischemic stroke, because increased susceptibility to a reduc-
tion in blood flow has been shown to be related to the de-
velopment of hypertension in this strain. An increased
infarct size in SHRs compared to normotensive controls
was observed in early and late stage hypertensive rats, but
not in pre-hypertensive rats [9].
Induction of ischemic stroke in conscious animals is
another crucial requirement for preclinical testing
according to the STAIR criteria, because most anes-
thetics are neuroprotective [10-12]. We have chosen to
use the endothelin (Et)-1 model [13] for induction of a
local reduction in blood flow in the middle cerebral ar-
tery (MCA), because this model allows induction of
vasoconstriction followed by reperfusion in conscious
rats.
In this study, we addressed the differences in
susceptibility to the induction of brain ischemia in con-
scious SHRs and normotensive controls using the Et-1
model. Since glial cells, such as microglia and astrocytes,
respond to ischemia and damage of neural tissues, we
especially focused on differences in activation of these
cells during stroke.
Material and methods
The et-1 rat model
Protocols for animal experiments were designed accord-
ing to the European Guidelines on Animal Experimenta-
tion and approved by the Ethical Committee for Animal
Experimentation of the Vrije Universiteit Brussel (VUB).
Male albino WKYRs and SHRs (Charles River Labora-
tories, Saint Germain sur l’Arbresle, France) were housed
in groups of four and allowed to acclimatize to their
new environment for one week until they weighed 275
to 300 g.
Surgery was performed as described previously by Van
Hemelrijck et al. [14]. Briefly, 24 h before Et-1 adminis-
tration, animals were anesthetized by an intraperitoneal
injection of a mixture of ketamine (75 mg/kg) and diaze-
pam (3.5 mg/kg) and placed on a stereotactic frame in
order to position a guide in the vicinity of the MCA.
The stereotactic coordinates were determined according to
the atlas of Paxinos and Watson [15] (coordinates relative
to bregma: AP +0.9 mm, L +5.0 mm and V +2.8 mm).
After surgery, rats received an intraperitoneal injection of
the analgesic ketoprofen (5 mg/kg) and were allowed to
recover overnight having free access to tap water and
standard laboratory chow. The next day, the guide was
replaced by a microdialysis probe of which the membrane
was removed (CMA, 3 mm, Solna, Sweden) through which
Et-1 (Sigma, St. Louis, MO, USA), dissolved in an iso-
osmotic Ringers’ solution, was perfused into the freely
moving animals at a rate of 1 μl/minute during six minutes.
Reduction in striatal blood flow by Et-1 is shown in
Figure 1A. Sham operated rats were injected with the same
volume of Ringer’s solution.
Neurological deficit score
In order to measure motoric and sensory deficits, the
Neurological Deficit Score (NDS) was measured as
described in Garcia et al. [16,17]. In this test, six para-
meters, including symmetry in the movement of the fore-
limbs, spontaneous activity, climbing, body proprioception,
response to vibrissae touch and fore paw outstretching,
were evaluated, resulting in a total score ranging from 3 to
18. The score is inversely related to the neurological deficit.
These parameters were assessed 24 h before injection of Et-
1 and at 1, 6, 24, 48 and 72 h after the insult.
Histology and immunohistochemistry
Rats were sacrificed at 24 or 72 h after the insult by intra-
peritoneal injection of an overdose of sodium pentobarbital
and then transcardially perfused for 5 minutes with 0.9%
sodium chloride followed by perfusion for 5 minutes with a
4% phosphate-buffered paraformaldehyde solution (pH
7.42) in order to fixate the brains. Next, animals were
decapitated and brains were post-fixed in paraformalde-
hyde. Brain slices of 50 μm were made and kept at 4 °C in a
preservative buffer solution (0.01 M phosphate buffered
saline (PBS) with 0.01% sodium azide).
To determine the infarct size, a series of equidistant
50 μm sections, comprising every fourth section, from
4.70 to 1.80 mm from bregma was collected, mounted
onto gelatin coated slices and stained with 0.5% Cresyl
Violet acetate. The infarct areas were outlined on digitized
images, after which the surface of these areas was calculated
using Image J software (NIH, version 1.43). Subsequently,
the infarct volume (v) in mm³ was estimated from the sur-
face areas (a) according to the Cavalieri principle for esti-
mation of volumes [18] using the following formula: v =d ×
Σa, where d is the distance between the upper (rostral) sur-
faces of two consecutive analyzed sections.
Activation of glial cells was assessed by immunohisto-
chemistry on 50 μm thick brain slices mounted on 3-
aminopropyltriethoxylane (APES)-coated slides using
antibodies against glial fibrillary acidic protein (GFAP)
as a marker for astrocytes and antibodies against ED-1
(CD68, a lysosomal glycoprotein) and Iba-1 (ionized cal-
cium binding adaptor molecule 1) for assessing micro-
glial activation. CD68 selectively stains activated
microglia and macrophages, whereas Iba-1 stains
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activated microglia more intensely than surveiling
microglia. Due to its expression on the cell surface Iba-1
also allows morphological identification of activated
microglia. Inducible nitric oxide synthase (iNOS) was
used as a marker of oxidative stress and inflammation.
The density of CD68- or Iba-1-stained cells in the stri-
atum and cortex was calculated in three coronal sections
from each rat, located between 0.90 mm and 0.20 mm
anterior to bregma to avoid interference caused by
implantation of the probe and expressed as the mean
number of cells per mm2. On CD68 stained sections, the
density of CD68 positive cells were assessed and on Iba-
1 stained sections, the densities of both round-shaped
cells and ramified microglia with thickened processes
were measured. In striatal sections, three different areas
were defined (Figure 1B). In each area the number of
cells was counted by using a counting grid and evaluated
by WCIF Image J (NIH, version 1.37). In the cortex, the
total number of cells was assessed on the surface be-
tween the lines crossing the center of the anterior com-
missures and the top of the striatum (Figure 1B). The
surface of this area was calculated by Image J software
(NIH, version 1.43). GFAP and iNOS staining were
quantified as followed: (intensity value contralateral stri-
atum (or cortex) – intensity value ipsilateral striatum (or
cortex)) using Image J software (NIH, version 1.43) in
the whole striatum and in the cortical region between
the reference lines. Calculating the difference between
the ipsi-and contralateral side is necessary to correct for
interassay variability in GFAP staining [17] (Figure 1B).
CD68, iba-1 and iNOS-staining
After preincubation at room temperature with 3%H202,
0.1% Triton X-100 and pre-immunized goat serum (1:5
dilution, Sigma), brain slices were incubated overnight at
4 °C with polyclonal mouse anti-CD68 (1:500 in normal
goat serum/PBS 1/5, AdB Serotec, Dusseldorf, Germany,
catalog number: MCA341R), anti-Iba-1 (1:1,000 in nor-
mal goat serum/PBS 1/5,Wako Pure Chemicals Indus-
tries, Osaka, Japan, catalog number: 019–19741) or anti-
iNOS (1:3,500 in normal goat serum/PBS 1/5, Millipore,
Temecula, CA, USA, catalog number: AB5382). The
next day, the slices were incubated for 4 h at room
temperature with a sheep anti-mouse IgG for the ED-1
staining (1:100 in normal goat serum/PBS 1/5, GE
Healthcare UK Limited, Little Chalfont, Buckingham-
shire, UK, catalog number: NA931V) or donkey anti-
rabbit IgG for Iba-1 and iNOS staining (1:100 in normal
goat serum/PBS 1/5, GE Healthcare UK Limited, Little
Chalfont, Buckinghamshire, UK, catalog number:
NA934V). Antibody binding was visualized using the
diaminobenzidine substrate chromogen kit (Dako Cyto-
mation, Glostrup, Denmark). Between all incubation
steps, washing steps were performed for five minutes
using PBS/0.1% Tween-20. For the iNOS staining, slices
were counterstained with 0.5% Cresyl Violet acetate after
assessing iNOS expression levels.
GFAP staining
After preincubation at room temperature with 0.1%H202,
normal donkey serum (1:10 dilution) and 0.1% Triton X-
100, brain slices were incubated for 24 h with polyclonal
rabbit anti-GFAP (1/10,000 in donkey serum/0.5% PBS
Dako, Glostrup, Denmark, catalog number: Z0334). Next,
slices were incubated for 1 h with a simple stain MAX
peroxidase-labeled anti-rabbit IgG (histofen, Nichirei Bio-
sciences Inc, Tokyo, Japan, catalog number: 414181 F).
Antibody binding was visualized using the diaminobenzi-
dine substrate chromogen kit (Dako, Glostrup, Denmark).
Between all incubation steps, washing steps were performed
for five minutes using PBS. Brain slices where mounted on
APES coated slices.
Figure 1 A: Differences in blood flow reduction in the striatum of anesthetized WKYRs and SHRs. Shown are differences in blood flow
reduction in the striatum of anesthetized WKYRs and SHRs after administration of 400 pmol Et-1. There were no differences between the two
strains. *Significantly different from baseline levels. Differences between SHR and WKY were not significant for all time points as assessed by the
unpaired Student’s t-test. (n = 4 for every group). B: Fixed fields in the striatum and cortex used for assessment of CD68 and GFAP expression. The
three fixed fields are indicated in the striatum. Each has an area of 1 mm2. Cells are counted in the three separate fields and the results are
expressed as mean number of cells/mm2. For the cortex, cells are counted between the reference lines. To determine the level of GFAP
expression, the relative intensity is measured in the whole striatum and in the cortical region between the reference lines.
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Laser Doppler flowmetry in anesthetized animals
For these experiments, it was not possible to work with
conscious animals. Since the sevoflurane used is neuro-
protective [11,12], a higher dose of Et-1 was necessary to
produce the same infarct as in awake animals. We con-
sidered 400 pmol as the optimal dose because of the in-
farct size and NDSs were comparable to the 200 pmol
without anesthesia (data not shown). After implantation
of the cannula for Et-1 administration (see section 1.1.),
a second probe was implanted in the striatum (coordi-
nates relative to bregma AP +1.2 mm, L +2.4 mm and V
+5 mm). After 24 h, rats were anesthetized with 4%
sevoflurane and oxygen 0.8 L/min into a transparent
chamber, placed on a heating blanket and maintained
under anesthesia using 2.5 to 3% sevoflurane delivered
with oxygen 0.8 L/minutes via a facemask during the en-
tire experiment. The Et-1 injection was injected as
described in section 2.1 and the probe in the striatum was
replaced by the Laser (Laser Flow Blood perfusion monitor
probe, TSI, Inc., Shoreview, MN, USA). Ten minutes after
reaching stable baseline levels, 400 pmol Et-1 was adminis-
tered and the blood flow was measured in the striatum for
90 minutes. Cerebral blood flow values are expressed as a
percentage of the mean pre-stroke baseline level.
The lipopolysaccharide rat model for neuroinflammation
Surgery for probe positioning in the striatum (coordinates
relative to bregma AP +1.2 mm, L +2.4 mm and V +2 mm)
was performed as described for Et-1 injection. One day
after surgery the guide was replaced by a probe as described
in section 1.1 and 2, 10 or 40 μg lipopolysaccharide (LPS)
(E. coli, Sigma, MO, USA, catalog number: L7895) dis-
solved in 0.9% saline was injected into the striatum at a rate
of 0.5 μl/minute during four minutes. Sham operated rats
were injected with the same volume of saline. Twenty four
hours after LPS administration, rats were sacrificed and
50 μm brain slices were made.
Statistics
All data are expressed as mean± SEM and statistical sig-
nificance between two groups was tested using the un-
paired Student’s t-test. Significant differences between
sham and Et-1 treated rats (WKYRs and SHRs) were
assessed using a one-way ANOVA followed by the Bon-
ferroni post-hoc test. In the LPS experiments, a one-way
ANOVA following by the Dunnett's Multiple Compari-
son post-hoc test was used. Differences in NDS were
assessed using the Mann–Whitney U-Test. Repeated
measures one-way ANOVA followed by the Dunnett's
post-test was applied to detect significant differences be-
tween pre- and post-stroke levels of striatal blood flow.
Statistical analysis was done using Graphpad Prism (ver-
sion 4.03, GraphPad Software, San Diego, CA, USA). All
tests were performed at the 0.05 level of significance.
Results
Induction of ischemic stroke in conscious WKYRs and
SHRs
We first performed a dose-range finding study in order to
induce an infarct situated in the striatum and cortex of con-
scious WKYRs. Bogaert et al. [13] found that a dose of 120
pmol Et-1 was necessary to produce such an infarct in nor-
mal Wistar rats. However, in WKYRs, 120 pmol did not in-
duce an infarct or significant sensory-motor deficits (data
not shown). Figure 2C shows that a dose of 180 pmol Et-1
induced an infarct of 31.7±1.9 mm³. However, the infarct
was restricted to the striatum. In contrast, a dose of 200
pmol induced an infarct of 41.8± 3.3 mm³ (Figure 2C),
which was present in both the striatum and cortex
(Figure 2A). At these doses there was no mortality, whereas
injection of 240 pmol Et-1 in WKYRs resulted in a morta-
lity of 57% (data not shown). A dose of 200 pmol also pro-
duced a significant neurological deficit for at least three
days in the WKYRs (Figure 3) and was, therefore, selected
for further studies.
Figure 2C also reveals that the SHRs initially produced
significantly larger infarcts in response to injection of
180 and 200 pmol Et-1 compared to the WKYRs. How-
ever, the difference between these strains was not
observed at 72 h after the insult, because the SHRs
showed a tendency towards a decrease in infarct size
after 24 h. In both strains, Et-1 injection evoked a sig-
nificant reduction in NDS compared to sham operated
animals at 1, 6, 24 h after the insult, which means 200
pmol induced sensory-motor deficits until at least one
day after stroke. The higher infarct volume in the SHRs at
24 h after the insult coincided with a significantly lower
NDS compared to normotensive controls (Figure 3). How-
ever, at later time points the reduction in NDS became
smaller and was not significant. This phenomenon is in line
with the decrease in infarct size after 72 h.
Et-1-induced reduction in striatal blood flow in WKYRs
and SHRs
To determine whether the increased infarct size in SHRs
was due to a stronger reduction in blood flow, we measured
the blood flow in the striatum of both strains. Every five
minutes, the blood flow was assessed and the reduction in
blood flow was expressed as a percentage of baseline levels.
In the WKYRs, Et-1 induced a significant reduction in
blood flow compared to baseline at 10, 15, 20 and 25 min-
utes after the insult. Blood flow was already decreased after
5 minutes and remained around 20% of normal levels be-
tween 15 and 25 minutes after the insult. After 60 minutes,
blood flow levels were back to normal. In the SHRs, blood
flow also decreased within 5 minutes after administration
of Et-1, but did not drop under 30% of the baseline levels.
Normal blood flow levels in SHRs were reestablished after
50 minutes. Although WKYRs showed a stronger decrease
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in blood flow in response to Et-1, the differences between
the two strains did not reach significance at any time point
(Figure 1A). Taken together, these findings indicate that
SHRs are more sensitive to reduction of striatal blood flow
resulting in an increased infarct size.
Microglia in SHRs are less susceptible to activation in
both the et-1 model for ischemic stroke and the LPS
model for neuroinflammation
Microglia are considered as the resident macrophages of
the brain and are the first cells in the brain responding to
Figure 2 Differences in infarct volume between WKYRs and SHRs. Representative micrographs (scale bar 1 cm) of infarcts in a WKYR and
SHR are shown in A and B, respectively. Brain slices were stained with Cresyl Violet 24 h after induction of the insult with 200 pmol Et-1. Graph C
shows the differences in infarct volume between WKYRs and SHRs assessed after induction of focal cerebral ischemia with 180 or 200 pmol Et-1.
*Significant difference between WKYRs and SHRs. ns: no significant difference between WKYRs and SHRs.
Figure 3 Neurological Deficit Scores in sham operated rats and Et-1 treated WKYRs and SHRs. Rats were injected with 200 pmol Et-1 and
the NDS was assessed at different time points. At 24 h, there was a significant difference between the NDS of the two strains.. *Significant
difference between WKYRs and SHRs. $ Significant difference between sham and Et-1 treated animals. ns: no significant difference between
WKYRs and SHRs. Group sizes were n = 6 to 13 at 1 h, n = 5 to 10 at 6 h, n = 13 to 15 at 24 h, n = 3 to 5 at 48 h and n= 4 to 6 at 72 h.
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ischemic injury gaining phagocytotic properties. They are
essential for neuroprotection, but can also induce detri-
mental processes, such as neuroinflammation and excessive
infiltration of leukocytes [19-22]. In order to compare the
activation of microglia in normotensive and hypertensive
rats, we performed immunohistochemistry using anti-
CD68 as a marker for phagocytotic microglia and
macrophages.
CD68 positive cells were only found within the infarct
zone. The density of these cells was low around the boun-
daries and stronger at the center of the infarct. The highest
levels were found in the transition zone between striatum
and cortex. This can be observed in the micrograph of
Figure 4A taken from the upper left area of the striatum
indicated in Figure 1B. It appears that most cells are present
on the left side of the micrograph, which is closest to the
cortex. CD68 expression in sham operated animals was
relatively low in the ipsilateral hemisphere (Figure 4G, H)
and absent in the contralateral hemisphere of all groups
(data not shown). Although the SHRs exhibited higher in-
farct volumes at 24 h, they expressed 50% less CD68 posi-
tive cells in the striatum at this time point (Figure 4G, D,
E). At 72 h, the density of CD68 positive cells in the stri-
atum was also reduced in the SHRs, although this differ-
ence did not reach statistical significance. Similar results
were observed in the cortex where the expression of CD68
was significantly lower in the SHRs (Figure 4F) compared
to WKYRs (Figure 4C) at both 24 and 72 h (Figure 4H).
Next, we addressed the activation of astrocytes using an
antibody against the commonly used activation marker
GFAP. At 24 and 72 h after Et-1 administration, there was
no significant difference between GFAP expression levels in
the striatum and cortex (no data at 72 h) of normotensive
and hypertensive rats. (Figure 5A, B).
Our observation that SHRs exhibit higher infarct volumes
in combination with a reduced activation of microglia,
Figure 4 Levels of CD68 positive cells in WKYRs and SHRs after Et-1 injection. Brain slices from WKYRs (n = 4) and SHRs (n = 4) treated with
200 pmol Et-1 were stained with anti-CD68 and the density of CD68+ cells was assessed in three fixed regions of the striatum and one region in
the cortex (see Figure 1B) . Representative micrographs from two fixed regions in the striatum (A and D, upper left region; B and E upper right
region) and one region in the cortex (C and F, in the center of the indicated region) are shown for WKYRs (A-C) and SHRs (D-F). Scale
bar = 50 μm. Densities of CD68+ cells in the striatum (G) and cortex (H) are provided for both strains. The expression of CD68 remained low in the
sham operated groups (n = 3 to 4 for the WKYR’s and n= 4 for the SHRs). *Significant difference between WKYRs and SHRs. $ Significant
difference between sham and Et-1 treated animals. ns: no significant difference between WKYRs and SHRs.
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suggests that microglia in SHRs are less susceptible to acti-
vation than their counterparts in normotensive rats. To test
this hypothesis, we assessed the effects of LPS on microglial
activation in both strains. LPS is a bacterial endotoxin act-
ing via direct stimulation of the Toll-like receptor (TLR),
which is commonly expressed in microglia and responsible
of their activation by several endogenous ligands including
intracellular components of dead cells including heat-shock
proteins and oligonucleotides [23,24]. By assessing micro-
glial responsiveness using LPS as a stimulus, indirect effects
via differences in blood flow reduction are completely
excluded. As shown in Figure 6C, it appears that microglia
of both strains equally responded to injection of a high dose
of LPS (40 μg). However, when 2 μg of LPS was injected,
the density of CD68 positive cells was markedly lower in
SHRs compared to WKYRs (Figure 6C). Figure 6A and B
show a lower density of CD68 positive cells in the SHRs
(Figure 6B) compared to the WKYRs (Figure 6A) in the
striatum after injection of 2 μg LPS. To confirm the idea
that the reduced density of CD68 positive cells was due to
impaired activation of microglia, another marker for acti-
vated microglia was tested. Antibodies against Iba-1 stain
activated microglia more intensely than their non-activated
counterparts and allow morphological identification of acti-
vated microglia. After labeling the slices of the rats that
were injected with 2 μg of LPS, three types of microglia
were distinguished: ramified microglia with thin processes
(Figure 6F, G), ramified microglia with thickened processes
and shortened endpoints (arrows in Figure 6D, E) and
round-shaped phagocytic cells (arrow heads in Figure 6D,
E). The first subset, representing resting microglia, was
mainly observed at the contralateral side of WKYRs
(Figure 6F) and SHRs (Figure 6G). At the ipsilateral side,
we measured the density of activated microglia with thick
processes and the round-shaped cells. We found that the
SHRs showed significantly reduced numbers of both sub-
types in the ipsilateral side (Figure 6H). To further address
possible consequences on oxidative stress and neuroinflam-
mation, we evaluated iNOS expression 24 h after injection
of 2 μg LPS using an antibody against iNOS. The difference
in total staining intensity between the two rat strains was
not significant although it seemed that the SHRs
(14.92±5.68) display lower levels of iNOS expression than
WKYRs (22.12±4.32) (data not shown, n=4 for both
groups). However, the most remarkable difference between
the two strains was that LPS injection in SHRs led to iNOS
expression in cells that were larger than the iNOS-
expressing cells in the normotensive controls (Figure 7A,
B). Indeed, counter staining with Cresyl Violet revealed a
remarkable difference in the predominant cell type expres-
sing iNOS. In WKYRs cells expressing iNOS were not
stained with Cresyl Violet (arrows in Figure 7C), while in
SHRs iNOS expressing cells were identified as neurons
(arrow heads in Figure 7D).
In contrast to the observations for microglia we found
that SHRs displayed a stronger activation of astrocytes in
response to LPS as assessed by anti-GFAP staining
(Figure 8).
Discussion
Using different animal models for ischemic stroke, sev-
eral groups showed that hypertensive rats are more vul-
nerable to cerebral ischemia than normotensive rats.
Hom et al. [9] found a 40% increase in infarct volume in
10- and 15-week old SHRs compared with age-matched
WKY controls in a 4 h filament model. Barone et al. [25]
observed that SHRs have higher cortical infarctions
compared to the controls and Marks et al. [26] found a
significant increase in infarct volume in SPSHRs com-
pared to the WKYRs. These experiments were all
Figure 5 GFAP expression levels in WKYRs and SHRs after Et-1 injection. Comparison of GFAP expression levels in the striatum (A) and
cortex (B) of WKYRs and SHRs after induction of focal cerebral ischemia with 200 pmol Et-1. There is no difference between the two rats at every
time point (n = 3 to 4 for the sham WKYRs and n= 4 to 5 for the Et-1 treated WKYRs and n= 3 to 4 for the sham SHRs and n= 4 to 5 for the Et-1
treated SHRs). *Significant difference between WKYRs and SHRs. $ Significant difference between sham and Et-1 treated animals. ns: no significant
difference between WKYRs and SHRs.
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performed in MCA occlusion models in which the blood
flow in the MCA was mechanically blocked by intrusion
of an intraluminal suture (filament model) [27,28].
In order to meet an important part of the STAIR criteria
for preclinical research on stroke, we used the Et-1 model
to reduce cerebral blood flow in conscious animals. In this
study, we addressed the differences in responses to cerebral
ischemia between conscious hypertensive SHRs and
normotensive WKYRs. We found that SHRs exhibit larger
infarct volumes compared to their controls 24 h after
administration of 180 and 200 pmol Et-1. Sensory-motor
behavior was tested with the NDS [16,17]. We tested the
animals at 1, 6, 24, 48 and 72 h after the insult. Sham
operated rats showed a small decrease in NDS, probably
due to surgery and implantation of the guide. In both rat
strains we observed a significant decrease in NDS com-
pared to the sham operated rats until 24 h after the insult.
The NDS of hypertensive rats, displaying increased infarct
sizes, was significantly lower than the NDS of WKY con-
trols at 24 h. Since 200 pmol induces larger infarct sizes,
while having a relatively small effect on striatal blood flow,
we postulate that the hypertensive model allows induction
of larger infarct sizes and maybe stronger deficits by in-
creasing the dose of Et-1. Using the normotensive model,
stronger effects can not be reached due to the high mortal-
ity rate at higher doses.
Figure 6 CD68 (A-C) and Iba-1 expression levels (D-H) in WKYRs and SHRs 24 hrs after injection of LPS. The expression of CD68 is shown
in a micrograph taken from a representative region in the striatum from WKYRs (A) and SHRs (B) and quantitative results are presented in the
graph C. (The number of animals per group were n = 3 for the sham WKYRs and n= 4 for the sham SHRs; n = 4 for the LPS-treated groups). The
expression of Iba-1 is shown for the ipsilateral (D, E) and contralateral hemispheres (F, G) for WKYRs (D, F) and SHRs (E, G). Graph H depicts
quantitative differences in Iba-1 expression in the striatum of WKYRs and SHRs at 24 h after injection of 2 μg LPS (n = 4 for the all groups).
*Significant difference between WKYRs and SHRs. $ Significant difference between sham and Et-1 treated animals. ns, no significant difference
between WKYRs and SHRs. Scale bar A, B = 50 μm; scale bar D-G= 50 μm, scale bar insert = 20 μm.
De Geyter et al. Journal of Neuroinflammation 2012, 9:114 Page 8 of 12
http://www.jneuroinflammation.com/content/9/1/114
It should be noted that the increased infarct size and
the reduction in NDS in SHRs compared to WKYRs dis-
appeared between Day 1 and Day 3 after the insult. A
possible explanation might be that the reduction in
blood flow in SHRs leads to a bigger infarct with a rela-
tively larger penumbral area at 24 h after ischemia,
which can be (partially) recovered.
The most commonly used rodent model for focal cere-
bral ischemia is blocking the blood flow in MCA by in-
sertion of an intraluminal suture [27,28]. In this model
reperfusion takes place directly after removal of the su-
ture. In contrast, in the Et-1 rat model, reduction in
blood flow in the MCA is induced by injection of the
vasoconstrictor Et-1 and reperfusion occurs spontan-
eously as a result of elimination of Et-1. In this model,
strain differences in sensitivity to Et-1 or in degradation
rate of Et-1 could lead to differences in the reduction of
the blood flow and, subsequently, to differences in in-
farct sizes [27]. Therefore, we investigated the effects of
Et-1 on blood flow in normotensive and hypertensive
rats. Since anesthetics are neuroprotective [10-12], a
higher dose of Et-1 was required. We showed that 400
pmol was the optimal dose, because it produced the
same infarct volume as the 200 pmol without anesthesia
(data not shown). In the WKYRs, this dose led to an
80% reduction of the blood flow and after 60 minutes
normal baseline values were reached. In the SHRs, Et-1
decreased the blood flow only by 65% and the normal
values where reached after 50 minutes. Taken together
these results indicate that the increased infarct volume
in SHRs observed at 24 h is not due to a stronger de-
crease on blood flow by injection of Et-1.
Since glial cells are strongly involved in both induction
of ischemic damage and neuroprotection [29], we also
compared the activation of microglia and astrocytes in
SHRs with their activation in WKY controls. Microglia
are the first cells to respond to ischemic damage [30].
Although anti-CD68 stains two types of phagocytotic
cells, activated microglia and infiltrated macrophages, it
is unlikely that differences in CD68 staining are due to
Figure 7 iNOS expression levels in WKYRs and SHRs 24 hrs after injection of 2 μg LPS. Brains slices from WKYRs (A) and SHRs (B) were
stained with an anti-iNOS antibody. C (WKY) and D (SHR) represent similar micrographs counterstained with Cresyl Violet and taken at a larger
magnification. Cells expressing iNOS are indicated by arrows (C) or arrow heads (neurons in 7D). Scale bar = 20 μm.
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differences in macrophage infiltration. It has been well
established in stroke models that until 72 h after the in-
sult, macrophages represent only a small minority of
CD68 positive cells [31]. For example, Shilling et al. [32]
showed, using chimeric mice expressing green fluores-
cent protein-expressing leukocytes, that less than 10% of
the CD68 positive cells during the first three days after
the insult are hematogeneous macrophages. Since the in-
farct size was significantly larger in SHRs, we conclude
that the reduced activation of microglial cells in these
rats is not due to a lower level of ischemic damage. We
hypothesize that microglial cells in SHRs are less suscep-
tible to triggers produced during the ischemic cascade,
such as ligands for the TLR-4 including heat-shock pro-
teins, RNA and extra-cellular matrix proteins. To assess
whether microglial cells in SHRs were less susceptible to
activation via TLR-4, we injected different amounts of
LPS into the striatum and measured the expression of
CD68. LPS is a bacterial endotoxin inducing a strong in-
flammatory response via binding to the TLR-4 and inter-
actions with CD14 and the lipopolysaccharide binding
protein. TLR-4 and CD14 are expressed by microglia
and ligation of these receptors leads to the activation
and differentiation of microglia towards phagocytotic
cells and subsequent production of neurotrophic factors,
pro- inflammatory cytokines via NF-кB [23,24,33].
Since administration of small amounts of LPS induced
a weaker expression of CD68 positive cells in SHRs
compared to WKYRs, we postulated that microglia in
SHRs are less susceptible for stimulation via TLR-4 at
suboptimal levels of ligands. Infiltration and activation
of monocytes within 24 h has been established in the
LPS model for neuroinflammation [34] and, therefore,
macrophages could be partially responsible for differ-
ences in CD68 expression between the two stains. In
order to allow morphological identification of activated
microglia, we also stained our slices from rats injected
with 2 μg LPS with anti-Iba-1. Since the density of acti-
vated microglia showing increased Iba-1 binding and
thickened processes was significantly increased in SHRs
compared to WKYRs, we conclude that microglia in
SHR rats are less sensitive to activation. The reduced
iNOS expression in glial cells from (not stained with
Cresyl Violet) LPS-treated SHRs is in accordance with
this idea and suggests that this phenomenon leads to a
diminution of neuroinflammation or oxidative stress. It
remains to be established whether the increased expres-
sion of iNOS in neurons contributes to the increased
susceptibility of SHRs to ischemic stroke at 24 h.
Based on the reduced levels of CD68 positive cells and
both Iba-1 positive subsets, we also conclude that the
total number of activated microglia in SHRs after injec-
tion of LPS is reduced compared to WKYRs.
We conclude that reduced sensitivity for microglial ac-
tivation may indeed explain the reduced expression of
CD68 in SHRs using the Et-1 model for stroke. Further
experiments are required to determine whether differ-
ences in TLR expression or signaling are responsible for
the reduced susceptibility of microglia in hypertensive
rats. Our observation that cerebral ischemia evoked a
lower level of CD68 expression in SHRs compared to
WKYRs is in contrast to the findings of Marks et al.
[26], who found that SHRSPs showed a more pro-
nounced microglial response to focal cerebral ischemia
compared to WKYRs in a permanent MCA occlusion
model. In that model, blood flow reduction is more se-
vere compared to our Et-1 model and permanent occlu-
sion leads to a stronger ischemic insult and possibly
stronger signals for microglial activation. This could ex-
plain, in part, the discrepancy between the results of
Marks et al. [26] and our observation because we
showed that only low levels of LPS exert different effects
in SHRs and WKYRs. It is intriguing to speculate that
the decreased microglial activation is responsible for the
increase in infarct sizes at 24 h after stroke. Indeed, in
addition to negative effects (for example, via induction
of neuroinflammation), microglia also exert beneficial
effects including phagocytosis of death cells, reuptake of
excitotoxic neurotransmitters and production of neuro-
trophic factors and anti-inflammatory cytokines (for ex-
ample, IL-10 and TGF-β) [19-22]. Lalancette-Hebert
et al. [35] even found that when microglia were com-
pletely ablated, the infarct volume increased.
Activated microglia release a variety of substances,
such as cytokines, which can lead to activation of
Figure 8 GFAP expression levels in WKYRs and SHRs 24 h after
injection of LPS. Comparison of GFAP expression levels in the
striatum of WKYRs and SHRs after injection of 2, 4 and 40 μg LPS in
the striatum (n = 3 for the sham WKY rats and n= 4 to 5 for the Et-1-
treated WKY rats and n = 4 for the sham SHRs and n= 4 for the Et-1
treated SHRs). * Significant difference between WKY and SHR. $
Significant difference between sham and Et-1 treated animals. ns: no
significant difference between WKY rats and SHRs.
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astrocytes. Ischemia activates astrocytes resulting in an
increasing expression of GFAP, which is also called re-
active gliosis [20,21,36,37]. In contrast to CD68, GFAP
expression in SHRs was not different compared to
normotensive controls. However, we cannot exclude the
possibility that astrocytes of SHRs are more responsive
to stimuli (see Figure 3B), but that the levels of stimula-
tory factors, for instance, released by microglia is
reduced. Data describing the differences in activation of
astrocytes in normotensive and hypertensive rats after
stroke are scarce, but it has been shown that there is less
GFAP expression in the putamen and cortex of young
SHRs until six months of age. Less astrocytes may be
present in these brain areas, but it is also possible that a
similar number of cells are present, but that the morph-
ology is changed [38]. At six months of age, a significant
increase of GFAP mRNA and an increase of GFAP
immunoreactivity were demonstrated in different brain
areas of SHRs compared to WKYRs [39].
We conclude that the Et-1 SHR model is a good pre-
clinical model for stroke, meeting the STAIR criteria.
This model allows testing of new therapies in conscious
animals with hypertension as a co-morbidity factor. The
difference in infarct size between normotensive and
hypertensive rats we observed using Et-1 to induce the
insult is in line with observations in other studies using
other methods to induce ischemia [9,25,26]. Another ad-
vantage of this model is that it includes spontaneous
reperfusion comparable to the clinical situation and that
the technique is less invasive compared to the other
models. For instance, in contrast to the filament model
[27,28], the Et-1 model does not lead to mechanical
damage of the endothelial layer of the vessel walls. Des-
pite the fact that the exact location of the guide strongly
influences the extent of blood flow reduction, we show
that the infarct sizes are reproducible [27]. We also
found that in the sham operated group, the activation of
microglia and astrocytes remained low, at least until
72 h after the insult, indicating that the implantation of
the guide alone hardly leads to inflammation within this
time frame. A disadvantage of the Et-1 model is that the
reduction in blood flow induced by a certain amount of
Et-1 may be strain dependent. These differences in sen-
sitivity to Et-1 should be taken into account when study-
ing the impact of co-morbidity factors, like hypertension
or diabetes, on treatments by comparing the efficacy of
these treatments in different rat strains.
Conclusions
Using the Et-1 model for ischemic stroke, we found that
microglia of hypertensive rats show a reduced suscepti-
bility to activation by LPS. Reduced microglial activation
in SHRs was also observed after induction of cerebral is-
chemia by Et-1. This difference is not due to reduced
infarct sizes, because infarcts were shown to be slightly
increased (24 h) or equal in SHRs. The reduced suscepti-
bility to microglial activation may be relevant with re-
spect to preclinical testing of stroke therapies, because
many potential drugs interact with microglia.
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